Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Surging Activase sustaining its clinical impact

Activase's market share began rising in April, after the 41,021-patient GUSTO study results indicated that patients given accelerated treatment with tPA plus heparin had 6.3 percent mortality compared with 7.3 percent

Read the full 314 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE